ConsumerLab sexual supplement review
This article was originally published in The Tan Sheet
Executive Summary
Nine of 22 sexual enhancement products (41%) pass 1ConsumerLab.com testing, online firm reports Sept. 24. Passing products, including six arginine and three yohimbe-based supplements, "were properly labeled, contained the claimed ingredients tested for and were not spiked with" Rx drug sildenafil, group says. Half the products were disqualified due to non-compliance with FDA labeling requirements, "such as incorrect or missing plant species names and/or no identification of the plant parts used," site explains. Several other supplements failed testing when they were found to contain significantly smaller percentage of active ingredient than claimed...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.